Investing.com - Bausch Health (TSX:BHC) reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Bausch Health...
Bausch Health Co. Inc. (BHC) reported Q3 EPS of $1.10, $0.16 better than the analyst estimate of $0.94. Revenue for the quarter came in at $2.05 billion versus the consensus...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
This article was written exclusively for Investing.com Purely from a fundamental perspective, Jumia Technologies (NYSE:JMIA) stock looks like a zero, or something close. Indeed,...
The coming trading week promises to be both busy and potentially volatile as a torrent of Wall Street's most prominant mega caps report quarterly metrics. The list includes...
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
| Average | 12.00 (+77.51% Upside) |
| High | 35 |
| Low | 6 |
| Price | 6.76 |
| No. of Analysts | 7 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Sell | Strong Sell | Sell |
| Technical Indicators | Sell | Buy | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Neutral | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 44.15 | 44.43 | 43.26 | +0.92 | +2.13% | 64.57K | Toronto | |||
| 17.13 | 17.34 | 17.13 | -0.04 | -0.23% | 4.80K | Toronto | |||
| 0.03 | 0.035 | 0.03 | 0.00 | 0.00% | 258.67K | CSE | |||
| 6.53 | 6.69 | 6.36 | -0.10 | -1.51% | 261.16K | Toronto | |||
| 47.26 | 47.53 | 46.86 | -0.05 | -0.11% | 70.78K | Toronto | |||
| 8.88 | 8.91 | 8.08 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 8.00 | 8.05 | 7.95 | -0.04 | -0.50% | 283.29K | Toronto | |||
| 14.84 | 14.93 | 14.79 | +0.03 | +0.20% | 34.26K | Toronto | |||
| 0.22 | 0.22 | 0.22 | 0.00 | 0.00% | 500.00 | TSXV | |||
| 16.59 | 17.52 | 16.47 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 0.025 | 0.025 | 0.025 | 0.00 | 0.00% | 0.00 | TSXV | |||
| 17.30 | 17.69 | 17.23 | -0.31 | -1.76% | 34.33K | Toronto | |||
| 8.76 | 9.15 | 8.66 | -0.19 | -2.12% | 633.08K | Toronto | |||
| 42.96 | 42.96 | 42.96 | -1.39 | -3.13% | 930.00 | Toronto | |||
| 11.31 | 11.86 | 11.26 | -0.54 | -4.56% | 709.52K | Toronto |